Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ronak H, Shah"'
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Andrew B. Katims, Andrew T. Lenis, Ronak H. Shah, Carissa E. Chu, Neha Ratna, Ashely M. Regazzi, Eugene J. Pietzak, David H. Aggen, Samuel A. Funt, Min Yuen Teo, Jonathan E. Rosenberg, Dean F. Bajorin, Timothy F. Donahue, Bernard H. Bochner, Michael F. Berger, David B. Solit, Gopa Iyer
Publikováno v:
Journal of Urology. 209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dff06dd8965b31ee146a69706f78a6d9
https://doi.org/10.1097/ju.0000000000003240.07
https://doi.org/10.1097/ju.0000000000003240.07
Autor:
Charles W. Ashley, Pier Selenica, Juber Patel, Michelle Wu, Josip Nincevic, Yulia Lakhman, Qin Zhou, Ronak H. Shah, Michael F. Berger, Arnaud Da Cruz Paula, David N. Brown, Antonio Marra, Alexia Iasonos, Amir Momeni-Boroujeni, Kaled M. Alektiar, Kara Long Roche, Oliver Zivanovic, Jennifer J. Mueller, Dmitriy Zamarin, Vance A. Broach, Yukio Sonoda, Mario M. Leitao, Claire F. Friedman, Elizabeth Jewell, Jorge S. Reis-Filho, Lora H. Ellenson, Carol Aghajanian, Nadeem R. Abu-Rustum, Karen Cadoo, Britta Weigelt
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
Purpose: We sought to determine whether sequencing analysis of circulating cell-free DNA (cfDNA) in patients with prospectively accrued endometrial cancer captures the mutational repertoire of the primary lesion and allows for disease monitoring. Exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f20600e69506798e18fdbe7fa82a2d2
https://pubmed.ncbi.nlm.nih.gov/36007103
https://pubmed.ncbi.nlm.nih.gov/36007103
Autor:
Adam J. Widman, Minita Shah, Nadia Øgaard, Cole C. Khamnei, Amanda Frydendahl, Aditya Deshpande, Anushri Arora, Mingxuan Zhang, Daniel Halmos, Jake Bass, Theophile Langanay, Srinivas Rajagopalan, Zoe Steinsnyder, Will Liao, Mads Heilskov Rasmussen, Sarah Østrup Jensen, Jesper Nors, Christina Therkildsen, Jesus Sotelo, Ryan Brand, Ronak H. Shah, Alexandre Pellan Cheng, Colleen Maher, Lavinia Spain, Kate Krause, Dennie T. Frederick, Murtaza S. Malbari, Melissa Marton, Dina Manaa, Lara Winterkorn, Margaret K. Callahan, Genevieve Boland, Jedd D. Wolchok, Ashish Saxena, Samra Turajlic, Marcin Imielinski, Michael F. Berger, Nasser K. Altorki, Michael A. Postow, Nicolas Robine, Claus Lindbjerg Andersen, Dan A. Landau
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of ctDNA fragments in low tumor fraction (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca96a3c3d9882a10f4e1302b660b4560
https://doi.org/10.1101/2022.01.17.476508
https://doi.org/10.1101/2022.01.17.476508
Autor:
Andrew B Katims, Andrew T Lenis, Ronak H. Shah, Carissa E Chu, Neha Ratna, Ashley M Regazzi, Eugene J. Pietzak, David H Aggen, Samuel A Funt, Min Yuen Teo, Jonathan E. Rosenberg, Dean F. Bajorin, Timothy F. Donahue, Bernard H. Bochner, Michael F. Berger, David B. Solit, Gopa Iyer
Publikováno v:
Journal of Clinical Oncology. 41:544-544
544 Background: Circulating ctDNA is associated with disease progression, worse overall survival, and recurrence in pts with bladder cancer. This study correlated targeted exome ctDNA sequencing with pathologic response to NAC and metastatic recurren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::287d67c00d398aee9b6805cd06ab5255
https://doi.org/10.1200/jco.2023.41.6_suppl.544
https://doi.org/10.1200/jco.2023.41.6_suppl.544
Autor:
Darren Cowzer, Ronak H. Shah, Sippy Punn, Laura Fiedler, April DeMore, Joanne F. Chou, Marinela Capanu, Michael F. Berger, Diane Reidy-Lagunes, Nitya Prabhakar Raj
Publikováno v:
Journal of Clinical Oncology. 41:653-653
653 Background: PanNENs represent 1-2% of all pancreatic neoplasms. The genomic landscape derived from PanNEN tumor tissue has been described previously. There are little data detailing the frequency of genetic alterations identified in cfDNA in an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49146f3fc342828f0d66d5a7bb37292c
https://doi.org/10.1200/jco.2023.41.4_suppl.653
https://doi.org/10.1200/jco.2023.41.4_suppl.653
Autor:
Beryl Manning-Geist, Juber Ahamad A Patel, Antonio Marra, Arnaud Da Cruz Paula, Etta J Hanlon, Nadeem Abu-Rustum, Ronak H. Shah, Michael F. Berger, Martee Leigh Hensley, Dmitriy Zamarin, Britta Weigelt, Claire Frances Friedman
Publikováno v:
Journal of Clinical Oncology. 40:5592-5592
5592 Background: Immune checkpoint inhibitors (ICI) targeting PD-1 have meaningful activity in microsatellite instability high (MSI-H), hypermutated or mismatch repair deficient (dMMR) advanced endometrial cancer (EC). We investigated if high-depth c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ad9de6dd44bcabd3a95401f2e1883fc
https://doi.org/10.1200/jco.2022.40.16_suppl.5592
https://doi.org/10.1200/jco.2022.40.16_suppl.5592
Autor:
James J. Harding, Sarina Anne Piha-Paul, Ronak H. Shah, James M. Cleary, David I. Quinn, Irene Brana, Victor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, James M. Ford, Daniel DiPrimeo, Michael F. Berger, Lisa DeFazio Eli, Funda Meric-Bernstam, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Journal of Clinical Oncology. 40:4079-4079
4079 Background: HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs) and are associated with poor overall survival (OS) in patients with metastatic disease. HER2 overexpression is associated with an increased risk of disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97d824c87fd28c270fdc6a850cf76c5c
https://doi.org/10.1200/jco.2022.40.16_suppl.4079
https://doi.org/10.1200/jco.2022.40.16_suppl.4079
Autor:
Darren Cowzer, Jessica B White, Pin-Jung Chen, Tae-Hyung Kim, Danny Khalil, Imane H. El Dika, Joanne F. Chou, Amin Yaqubie, Joseph S. Light, Jinru Shia, Hooman Yarmohammadi, Joseph Patrick Erinjeri, Marinela Capanu, Richard K. G. Do, David B. Solit, Ronak H. Shah, Michael F. Berger, Ghassan K. Abou-Alfa, James J. Harding
Publikováno v:
Journal of Clinical Oncology. 40:4110-4110
4110 Background: HCC is often diagnosed based on high-quality cross-sectional imaging, and when a biopsy is pursued, acquisition of tissue may be of limited quantity and quality or complicated by underlying medical comorbidities. NGS of tumor derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37be3ab39c68504b06f142ad6e9805f2
https://doi.org/10.1200/jco.2022.40.16_suppl.4110
https://doi.org/10.1200/jco.2022.40.16_suppl.4110
Autor:
Guilherme Harada, Noura J. Choudhury, Alison M. Schram, Ezra Rosen, Yonina R. Murciano-Goroff, Christina J. Falcon, Clare Wilhelm, Lauren A. Kaplanis, Dazhi Liu, Jason C. Chang, Soo-Ryum Yang, Aradhika Dhawan, Patrick Evans, Casey Savin, Grace Grimaldi, Ronak H. Shah, Emiliano Cocco, Alexander E. Drilon
Publikováno v:
Journal of Clinical Oncology. 40:3104-3104
3104 Background: First-generation TRK tyrosine kinase inhibitors (TKIs) are approved in a tumor-agnostic fashion in more than 40 countries for patients with NTRK fusion-positive adult and pediatric cancers. While resistance to these agents has previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f86c1ddbbe8a91ba787c26a07d21c57
https://doi.org/10.1200/jco.2022.40.16_suppl.3104
https://doi.org/10.1200/jco.2022.40.16_suppl.3104